FY2025 Earnings Estimate for BDX Issued By Zacks Research

Becton, Dickinson and Company (NYSE:BDX) – Analysts at Zacks Research decreased their FY2025 earnings per share (EPS) estimates for Becton, Dickinson and Company in a research report issued on Thursday, April 10th. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will post earnings of $14.40 per share for the year, down from their previous estimate of $14.43. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.43 per share. Zacks Research also issued estimates for Becton, Dickinson and Company’s Q3 2026 earnings at $4.05 EPS, Q4 2026 earnings at $4.52 EPS, FY2026 earnings at $15.55 EPS, Q2 2027 earnings at $4.14 EPS and FY2027 earnings at $16.79 EPS.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%.

Several other equities research analysts have also recently commented on BDX. Barclays dropped their target price on shares of Becton, Dickinson and Company from $279.00 to $261.00 and set an “overweight” rating for the company in a research report on Monday, April 7th. Piper Sandler boosted their price objective on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 28th. Finally, StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 2nd. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $275.71.

Becton, Dickinson and Company Price Performance

BDX opened at $202.02 on Monday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13. The stock has a market capitalization of $58.01 billion, a PE ratio of 33.56, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35. The stock’s 50 day moving average price is $222.67 and its 200-day moving average price is $229.37. Becton, Dickinson and Company has a 52-week low of $193.03 and a 52-week high of $251.99.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 31st. Investors of record on Monday, March 10th were given a dividend of $1.04 per share. The ex-dividend date of this dividend was Monday, March 10th. This represents a $4.16 annualized dividend and a yield of 2.06%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 69.10%.

Becton, Dickinson and Company announced that its board has authorized a stock buyback plan on Tuesday, January 28th that authorizes the company to buyback 10,000,000 shares. This buyback authorization authorizes the medical instruments supplier to buy shares of its stock through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.

Insider Activity

In related news, EVP Richard Byrd sold 459 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $230.00, for a total transaction of $105,570.00. Following the transaction, the executive vice president now owns 6,952 shares in the company, valued at approximately $1,598,960. The trade was a 6.19 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael David Garrison sold 597 shares of the company’s stock in a transaction dated Friday, January 17th. The stock was sold at an average price of $236.51, for a total value of $141,196.47. Following the completion of the transaction, the executive vice president now directly owns 5,544 shares of the company’s stock, valued at approximately $1,311,211.44. This trade represents a 9.72 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 4,675 shares of company stock valued at $1,057,182 in the last 90 days. Company insiders own 0.36% of the company’s stock.

Hedge Funds Weigh In On Becton, Dickinson and Company

Several institutional investors have recently bought and sold shares of the business. Wesbanco Bank Inc. lifted its position in Becton, Dickinson and Company by 1.9% in the fourth quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier’s stock worth $580,000 after buying an additional 48 shares during the last quarter. S.A. Mason LLC grew its stake in shares of Becton, Dickinson and Company by 3.7% during the fourth quarter. S.A. Mason LLC now owns 1,414 shares of the medical instruments supplier’s stock valued at $321,000 after buying an additional 50 shares during the last quarter. Hillsdale Investment Management Inc. grew its position in Becton, Dickinson and Company by 1.7% in the 4th quarter. Hillsdale Investment Management Inc. now owns 3,060 shares of the medical instruments supplier’s stock valued at $694,000 after acquiring an additional 50 shares during the last quarter. Americana Partners LLC lifted its position in shares of Becton, Dickinson and Company by 3.5% during the fourth quarter. Americana Partners LLC now owns 1,520 shares of the medical instruments supplier’s stock worth $345,000 after purchasing an additional 52 shares during the last quarter. Finally, Alpha Omega Wealth Management LLC grew its holdings in shares of Becton, Dickinson and Company by 5.7% in the first quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier’s stock worth $225,000 after purchasing an additional 53 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.